S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself

ImmuPharma Share Price, News & Analysis (LON:IMM)

GBX 1.56
-0.17 (-9.98%)
(As of 11/29/2023 09:21 PM ET)
Compare
Today's Range
1.51
1.65
50-Day Range
1.54
2.05
52-Week Range
1.36
3.80
Volume
686,488 shs
Average Volume
1.28 million shs
Market Capitalization
£6.50 million
P/E Ratio
N/A
Dividend Yield
0.77%
Price Target
N/A

IMM stock logo

About ImmuPharma Stock (LON:IMM)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

IMM Stock Price History

IMM Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
ImmuPharma shares jump 6.5% after FDA update
ImmuPharama eyes clinical trial progress
ImmuPharma eyes clinical trial progress
ImmuPharma "looking forward" to upcoming FDA meetings
ImmuPharma partner gets FDA meeting date
ImmuPharma rises 4% after it reveals headway with lead asset
See More Headlines
Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/30/2020
Today
11/30/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
£-2,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£94,819.00
Cash Flow
GBX 0.08 per share

Miscellaneous

Free Float
N/A
Market Cap
£6.50 million
Optionable
Not Optionable
Beta
1.39
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Timothy Paul McCarthy XIV (Age 66)
    FCCA, M.B.A., MBA, Chairman & CEO
    Comp: $106.5k
  • Dr. Timothy Gary Franklin M.B.A.
    Ph.D., COO & Director
  • Ms. Lisa Baderoon
    Head of Investor Relations & Non Executive Director
  • Dr. Jean-Marie Geiger PharmD
    MD, Head of Clinical Development
  • Dr. Laura Mauran-Ambrosino
    Chief Scientific Officer of ImmuPharma Biotech
  • Ms. Lara E. Sucheston-Campbell
    Head of Clinical & Medical Affairs
  • Dr. Sébastien R. Goudreau Ph.D.
    CEO of ImmuPharma Biotec & Director














IMM Stock Analysis - Frequently Asked Questions

How have IMM shares performed in 2023?

ImmuPharma's stock was trading at GBX 1.84 at the start of the year. Since then, IMM shares have decreased by 15.2% and is now trading at GBX 1.56.
View the best growth stocks for 2023 here
.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) posted its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:IMM) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -